Merck & Co licenses Japan Tobacco's novel osteoporitic
This article was originally published in Scrip
Merck & Cohas acquired the global rights outside Japan to a novel compound for osteoporosis being developed by Japan Tobacco (JT). The move should help to shore up the US firm's franchise in this therapeutic area following the loss of exclusivity for Fosamax (alendronate) earlier this year.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.